enpatoran
Small moleculeexperimental
Clinical trial activity
10 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
6
Phase 2
4
Phase 3
0
Phase 4
0
Earliest trial started Sep 18, 2018 (NCT03676322)
Timeline
Indications
Mechanism of action
- Toll-like receptor 7ANTAGONIST
Toll-like receptor 7 antagonist
- Toll-like receptor 8ANTAGONIST
Toll-like receptor 8 antagonist
Chemistry & pharmacology
Loading structure…
SMILES
N#Cc1ccc(N2C[C@H](N)C[C@H](C(F)(F)F)C2)c2cccnc12- Mol. weight
- 320.32 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4802159 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06589713 | Phase 1 | Sep 23, 2024 | Merck KGaA |
| NCT06589726 | Phase 1 | Sep 10, 2024 | Merck KGaA |
| NCT05650567 | Phase 2 | Dec 15, 2022 | Merck KGaA, Merck Serono |
| NCT05540327 | Phase 2 | Sep 16, 2022 | Merck KGaA |
| NCT05162586 | Phase 2 | Dec 17, 2021 | Merck KGaA, Merck Serono |
| NCT05110027 | Phase 1 | Nov 2, 2021 | Merck KGaA |
| NCT04880213 | Phase 1 | May 6, 2021 | Merck KGaA |
| NCT04647708 | Phase 1 | Jan 4, 2021 | Merck KGaA |
| NCT04448756 | Phase 2 | Jul 29, 2020 | Merck KGaA, Merck Serono |
| NCT03676322 | Phase 1 | Sep 18, 2018 | Merck KGaA |
Showing 10 of 10 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Merck KGaA | For profit | 10 | 7 | 2 | 2018 |
| Merck Serono | For profit | 3 | 3 | 1 | 2020 |
2 organizations
Page 1 / 1